Profit Distribution Plan - The company plans to distribute a cash dividend of 2.00 yuan per 10 shares (including tax) [1] - The profit distribution is based on the total share capital registered on the equity distribution record date, with specific dates to be announced later [1] - The total share capital as of June 30, 2025, is 404,593,314 shares, resulting in a profit distribution ratio of 43.15% [1] Financial Performance - For the first half of 2025, the company reported a net profit attributable to shareholders of 187,524,723.49 yuan [1] - As of June 30, 2025, the company's undistributed profits amounted to 359,777,802.90 yuan in the parent company report and 689,367,472.63 yuan in the consolidated report [1] Decision-Making Process - The company's board of directors approved the profit distribution plan during the ninth meeting of the second board on August 18, 2025, with a unanimous vote of 5 in favor [2] - The supervisory board also approved the plan during its sixth meeting on the same day, with a unanimous vote of 3 in favor, stating that the plan considers the company's future development and funding needs [2]

Group 1 - The number of confirmed cases of Chikungunya fever in Shunde, Guangdong has reached 2,934, primarily affecting Lecong, Beijiao, and Chen Village, all of which are mild cases [1][2] - The World Health Organization has issued a warning regarding the potential for widespread outbreaks of Chikungunya fever, with 119 countries and regions reporting cases, putting approximately 5.5 million people at risk [2][3] - Local governments in Guangdong are actively promoting mosquito control measures, including public announcements urging citizens to eliminate mosquito breeding sites and participate in coordinated mosquito eradication efforts [2][3] Group 2 - The "mosquito repellent concept" has gained traction in the capital markets, with stocks related to mosquito control and testing reagents seeing significant increases [5][6] - Companies such as Rainbow Group and Kangzhi Pharmaceutical have experienced stock price surges, while others like Runben Co., Shanghai Jahwa, and Qingsong Co. have also seen gains [6] - Several companies, including Rendu Biotech and Mindray, have highlighted their mosquito-borne virus testing products, indicating a growing market interest in diagnostic tools for diseases like Chikungunya [6]